The asset has secured FDA fast track, rare paediatric disease and orphan drug product designations, and has been accepted into the FDA’s Rare Disease Evidence Principles programme. As part of the deal, Actio Biosciences will spin out a new private company focused on genetic rare neurological diseases, retaining certain personnel and assets except for ABS-1230. Jazz Pharmaceuticals president and CEO Renee Gala said: “The acquisition of ABS-1230 represents a highly strategic expansion of our rare epilepsy portfolio, building upon the global success of Epidiolex and deepening our leadership in rare and severe epilepsies.